SCHEMBL1002996

SCHEMBL1002996

COCCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.42
▸ PDE4A P27815 1/20 0.42
▸ RECQL P46063 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ GAA P10253 2/20 0.39
▸ EPHX2 P34913 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ GPBAR1 Q8TDU6 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32669008 1.00 TSHR (0.45) TSHRALDH1A1PDE4ARECQLLMNA
Butyl Alcohol SCHEMBL28237100 0.88 TSHR (0.36) TSHRALDH1A1PDE4ARECQLLMNA
SCHEMBL9321565 0.85 PDE4A (0.52) ALDH1A1PDE4ALMNAMEN1USP2
SCHEMBL9323008 0.85 PDE4A (0.52) ALDH1A1PDE4ALMNAMEN1USP2
SCHEMBL8991473 0.85 PDE4A (0.52) ALDH1A1PDE4ALMNAMEN1USP2
SCHEMBL8762542 0.83 PDE4A (0.50) ALDH1A1PDE4ALMNAMEN1USP2
SCHEMBL3517475 0.83 PDE4A (0.50) ALDH1A1PDE4ALMNAMEN1USP2
SCHEMBL8763289 0.83 PDE4A (0.50) ALDH1A1PDE4ALMNAMEN1USP2
SCHEMBL3517791 0.83 PDE4A (0.50) ALDH1A1PDE4ALMNAMEN1USP2
SCHEMBL8763069 0.83 PDE4A (0.50) ALDH1A1PDE4ALMNAMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651199-A4 METHOD AND PREPARATION FOR REDUCING IRRITATION AND/OR INFLAMMATORY REACTION IN HUMAN SKIN PCR TECHNOLOGY HOLDINGS LC (US) 2008-08-20 — — EP claimed
US-20080131386-A1 Topical product formulations containing strontium for reducing skin irritation COSMEDERM TECHNOLOGIES, INC. (US) 2008-06-05 — — US claimed
EP-1651199-A1 METHOD AND PREPARATION FOR REDUCING IRRITATION AND/OR INFLAMMATORY REACTION IN HUMAN SKIN PCR Technology Holdings, LC (US) 2006-05-03 — — EP claimed
US-20050197407-A1 Method and preparation for reducing irritation and/or inflammatory reaction in human skin PCR TECHNOLOGY HOLDINGS, LC (US) 2005-09-08 — — US claimed
WO-2005079775-A1 METHOD AND PREPARATION FOR REDUCING IRRITATION AND/OR INFLAMMATORY REACTION IN HUMAN SKIN PCR TECHNOLOGY HOLDINGS, LC (US) 2005-09-01 — — WO claimed
EP-0801570-B1 FORMULATIONS AND METHODS FOR REDUCING SKIN IRRITATION COSMEDERM TECHNOLOGIES (US) 2004-12-08 — — EP claimed
EP-1136065-B1 Formulations and methods for reducing skin irritation COSMEDERM TECHNOLOGIES (US) 2004-11-24 — — EP claimed
US-20030147975-A1 Pharmaceutical composition which produces irritation JOSHI YATINDRA (US) 2003-08-07 — — US claimed
US-20030124202-A1 Formulations and methods for reducing skin irritation SENSORY SYSTEMS 2003-07-03 — — US claimed
EP-0801554-B1 FORMULATIONS AND METHODS FOR REDUCING SKIN IRRITATION COSMEDERM TECHNOLOGIES (US) 2003-04-16 — — EP claimed
WO-1996019228-A1 FORMULATIONS AND METHODS FOR REDUCING SKIN IRRITATION COSMEDERM TECHNOLOGIES (US) 1996-06-27 — — WO claimed
EP-0338565-B1 N-Alkoxyalkylamides of hydroxyacids and skin treating compositions therewith REVLON CONSUMER PROD CORP (US) 1994-08-10 — — EP claimed
EP-0580453-A2 Hair-care compositions containing N-alkoxyalkylamides Revlon Consumer Products Corporation (US) 1994-01-26 — — EP claimed
US-5139771-A Hydrolyzed grain product, seaweed derivative, water REVLON, INC. (US) 1992-08-18 — — US claimed
US-5084270-A Moisturizing and/or softening cosmetics for skin treatment REVLON, INC. (US) 1992-01-28 — — US claimed
WO-1991000083-A1 SKIN CARE PREPARATION REVLON, INC. (US) 1991-01-10 — — WO claimed
US-4973473-A Skin care preparation REVLON, INC. (US) 1990-11-27 — — US claimed
EP-0366753-A4 N-ALKOXYALKYLAMIDES AND COSMETIC TREATING COMPOSITIONS THEREWITH. REVLON (US) 1990-06-27 — — EP claimed
EP-0366753-A1 N-ALKOXYALKYLAMIDES AND COSMETIC TREATING COMPOSITIONS THEREWITH REVLON, INC. (US) 1990-05-09 — — EP claimed
WO-1989010121-A1 N-ALKOXYALKYLAMIDES AND COSMETIC TREATING COMPOSITIONS THEREWITH REVLON, INC. (US) 1989-11-02 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197407-A1 Method and preparation for reducing irritation and/or inflammatory reaction in human skin IL1B, IL17A, HSD17B7 TSHR 3549/4885ALDH1A1 1787/4885PDE4A 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback